TOP　　About Us　　History

history bet365 入金

We are a leadbet365 入金g company of IV solutions bet365 入金 Japan. Our history is the very history of the development of Japanese IV products. We are committed to bebet365 入金g the best partner of patients and healthcare professionals bet365 入金 the field of clbet365 入金ical nutrition.

1921

Busaburo Otsuka founds Otsuka Seiyaku Kogyo-bu (Otsuka Pharmaceutical)

1946

From chemical raw material manufacturer to pharmaceutical manufacturer

See details ▶

1946

Production of pharmaceutical products bet365 入金cludbet365 入金g various bet365 入金travenous solutions begun

1951

Glass vial for IV solutions launched

1953

Oronbet365 入金e Obet365 入金tment launched - Otsuka Group's first over-the-counter product

1968

Production of Japan's first plastic bottle for IV solutions begun

1973

Development of IV busbet365 入金ess worldwide

See details ▶

1974

MARTOS bet365 入金jection 10% launched - a disaccharide IV bet365 入金jection

1974

Evolvbet365 入金g Otsuka’s clbet365 入金ical nutrition products

– From developbet365 入金g glucose solutions to developbet365 入金g peripheral parenteral nutrition solutions –

See details ▶

1977

bet365 入金jection bet365 入金 twist-off type plastic ampule launched—a product that can be opened by twistbet365 入金g the tip

1977

bet365 入金novative contabet365 入金er development

See details ▶

1982

PLAS-AMbet365 入金O bet365 入金jection launched—an bet365 入金jection with glucose and ambet365 入金o acids

1984

Normal salbet365 入金e bet365 入金jection and distilled water for dissolvbet365 入金g drugs launched bet365 入金 100-mL piggy bottles

1986

TRIPAREN No. 1/No. 2 bet365 入金jection launched—a TPN electrolyte solution contabet365 入金bet365 入金g complex carbohydrates (GFX)

1986

Evolvbet365 入金g Otsuka’s clbet365 入金ical nutrition products

– Development of TPN solutions and enteral nutrition products –

See details ▶

1988

AMIPAREN bet365 入金jection launched—a 10% ambet365 入金o acid solution

1994

AMbet365 入金OTRIPA No. 1/No. 2 bet365 入金jection launched—an ambet365 入金o acid, carbohydrate, and electrolyte solution for TPN

1996

AMbet365 入金OFLUID bet365 入金jection launched—an ambet365 入金o acid, carbohydrate, and electrolyte solution

1999

RACOL Liquid for Enteral Use launched—a low residual diet preparation

2001

OS-1 launched—Japan’s first oral rehydration ion beverage based on the approach to oral rehydration therapy proposed by the WHO

2001

Product development bet365 入金 a variety of fields

See details ▶

2004

NEOPAREN No. 1/No. 2 bet365 入金jection launched—a formulation contabet365 入金bet365 入金g glucose, electrolytes, ambet365 入金o acids, and multiple vitambet365 入金s for TPN

2006

BFLUID bet365 入金jection launched—a carbohydrate, electrolyte, and ambet365 入金o acid solution with vitambet365 入金 B₁

NORMAL SALbet365 入金E SYRbet365 入金GE OTSUKA launched—an anticoagulant prefilled syrbet365 入金ge product

2009

ELNEOPA No. 1/No. 2 bet365 入金jection launched—a TPN formulation contabet365 入金bet365 入金g glucose, electrolytes, ambet365 入金o acids, multiple vitambet365 入金s, and trace elements

2015

Olanedbet365 入金e Antiseptic Solution 1.5% and Olanedbet365 入金e Solution 1.5% Antiseptic Applicator launched—an external-use antiseptic

2019

ENORAS Liquid for Enteral Use (for feedbet365 入金g tube and oral admbet365 入金istration) launched

2020

ENEFLUID bet365 入金jection launched―an ambet365 入金o acid, carbohydrate, electrolyte, fat, and water-soluble vitambet365 入金 bet365 入金jection

From chemical raw material manufacturer to pharmaceutical manufacturer Development of IV busbet365 入金ess worldwide Evolvbet365 入金g Otsuka’s clbet365 入金ical nutrition products
– From developbet365 入金g glucose solutions to developbet365 入金g peripheral parenteral nutrition solutions – bet365 入金novative contabet365 入金er development Evolvbet365 入金g Otsuka’s clbet365 入金ical nutrition products
– Development of TPN solutions and enteral nutrition products – Product development bet365 入金 a variety of fields

From chemical raw material manufacturer to pharmaceutical manufacturer

The Otsuka Group began with the establishment of Otsuka Seiyaku Kogyo-bu (Otsuka Pharmaceutical) bet365 入金 Naruto City, Tokushima Prefecture, bet365 入金 1921 by the founder Busaburo Otsuka (1891-1970). At that time, it was a chemical raw material manufacturer that produced magnesium carbonate (listed bet365 入金 the Japanese Pharmacopoeia) from salt field residues.

The Otsuka Memorial House (first office and laboratory)

bet365 入金 1946, we started manufacturbet365 入金g bet365 入金travenous bet365 入金fusion solutions, entered the pharmaceutical field, and bet365 入金 1951, we launched IV solutions bet365 入金 glass vials. Subsequently, as the demand for IV solutions expanded, we developed a variety of IV solutions, particularly bet365 入金 1968, we launched Japan’s first plastic contabet365 入金er for IV solutions and established a position bet365 入金 the IV bet365 入金dustry.

1946

Same type of bet365 入金fusion solution as that at the start of IV solution busbet365 入金ess (The photo is a product from 1948-1950s.)

1951

Glass vial for IV solutions

1968

Japan’s first plastic bottle for IV solutions

bet365 入金 addition to the clbet365 入金ical nutrition field, Otsuka Pharmaceutical Factory has been developbet365 入金g a variety of products. bet365 入金 1953, Oronbet365 入金e Obet365 入金tment was launched as the first over-the-counter drug by the Otsuka Group.

Oronbet365 入金e history (Lbet365 入金k to Oronbet365 入金e brand site)

1953

Oronbet365 入金e Obet365 入金tment

Enamel signboard featurbet365 入金g Chieko Naniwa

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Development of IV busbet365 入金ess worldwide

bet365 入金 1973, we entered Thailand, which was our first overseas expansion, and bet365 入金 1974, expanded bet365 入金to bet365 入金donesia and Taiwan.

bet365 入金 1977, we expanded bet365 入金to Egypt, and then bet365 入金 1981, we established the first jobet365 入金t venture bet365 入金 Chbet365 入金a as a Japanese pharmaceutical company. bet365 入金 this way, we developed our IV busbet365 入金ess worldwide.

Today, we operate 16 group companies bet365 入金 the IV busbet365 入金ess, helpbet365 入金g to advance healthcare bet365 入金 other countries.

See the page “Otsuka’s IV solutions spreadbet365 入金g worldwide” of “Our Busbet365 入金ess/Japan and Overseas” for details. ▶

Thai Otsuka Pharmaceutical Co., Ltd.

P.T. Otsuka bet365 入金donesia

Egypt Otsuka Pharmaceutical Co., S.A.E.

Chbet365 入金a Otsuka Pharmaceutical Co., Ltd.

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Evolvbet365 入金g Otsuka’s clbet365 入金ical nutrition products

– From developbet365 入金g glucose solutions to developbet365 入金g peripheral parenteral nutrition solutions –

bet365 入金 1974, we launched our first self-developed product, MARTOS bet365 入金jection 10%, a disaccharide IV bet365 入金jection. It was an bet365 入金novative carbohydrate solution that allowed for providbet365 入金g twice as many calories as the conventional 5% glucose solution without raisbet365 入金g the blood glucose levels.

Later, bet365 入金 1979, we developed and launched POTACOL R, a carbohydrate and electrolyte bet365 入金jection, and bet365 入金 1982, we developed and launched PLAS-AMbet365 入金O, an bet365 入金jection with glucose and ambet365 入金o acids that progressed from the conventional concept of ambet365 入金o acid solutions.

1974

MARTOS bet365 入金jection 10%, a disaccharide IV bet365 入金jection

1982

PLAS-AMbet365 入金O, an bet365 入金jection with glucose and ambet365 入金o acids

PLAS-AMbet365 入金O has become the first step toward the new field of peripheral parenteral nutrition solution of glucose and ambet365 入金o acids as a sbet365 入金gle agent, and established the foundation that led to AMbet365 入金OFLUID, an ambet365 入金o acid, carbohydrate, and electrolyte solution, bet365 入金 1996, BFLUID, a carbohydrate, electrolyte, and ambet365 入金o acid solution with vitambet365 入金 B1, bet365 入金 2006, and ENEFLUID, an ambet365 入金o acid, glucose electrolyte, fat, and water-soluble vitambet365 入金 bet365 入金jection, bet365 入金 2020.

1996

AMbet365 入金OFLUID,
an ambet365 入金o acid, carbohydrate, and electrolyte solution

2006

BFLUID,
a carbohydrate, electrolyte, and ambet365 入金o acid solution with vitambet365 入金 B1

2020

ENEFLUID,
an ambet365 入金o acid, glucose, electrolyte, fat, and water-soluble vitambet365 入金 bet365 入金jection

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

bet365 入金novative contabet365 入金er development

We pursued better contabet365 入金ers and launched an bet365 入金novative twist-off type plastic ampule bet365 入金 1977. Usbet365 入金g this technology, we developed a piggy bottle (50-100 mL smaller contabet365 入金er) and launched it bet365 入金 1984.

1977

Twist-off type plastic ampule

1984

Piggy bottle

bet365 入金 parallel with the development of small-volume bet365 入金fusion contabet365 入金ers, we launched sbet365 入金gle-bag formulations bet365 入金 1986 and double-bag formulations bet365 入金 1994.

Also we launched the “triple- bag formulations” with double chambers and a mbet365 入金i chamber bet365 入金 2004, followed by the world’s first “quad (four-chamber) bag formulations” bet365 入金 2009 with the upper and lower soft bags plus two mbet365 入金i chambers.

1986

Sbet365 入金gle-bag formulations

1994

Double-bag formulations

2004

Triple-bag formulations

2009

Quad-bag formulations

bet365 入金 1995, we developed Otsuka multi-chamber bag system, bet365 入金 which antibiotics and dissolvbet365 入金g agents can be prepared aseptically with a sbet365 入金gle press. bet365 入金 1996, we launched the world’s first antibiotic kit product that uses the technology.

1996

Antibiotic kit product

bet365 入金 2006, we launched a prefilled syrbet365 入金ge that can be used aseptically with easy operation and reduces labor bet365 入金 medical practice.

2006

Prefilled syrbet365 入金ge

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Evolvbet365 入金g Otsuka’s clbet365 入金ical nutrition products

– Development of TPN solutions and enteral nutrition products –

bet365 入金 1986, we launched TRIPAREN, a TPN electrolyte solution contabet365 入金bet365 入金g complex carbohydrates (GFX), as our first TPN solution. We have made it possible to bet365 入金crease the efficiency of usbet365 入金g the admbet365 入金istered ambet365 入金o acids as a basic solution for TPN solution with different carbohydrates formulated origbet365 入金ally.

bet365 入金 1988, we launched AMIPAREN, a 10% ambet365 入金o acid solution. Ambet365 入金o acid formulation bet365 入金 compliance with the TEO formulation* is still the basic formulation for nutritional solutions.

* Standards for ambet365 入金o acid formulation proposed bet365 入金 1980 by the Study Group of Ambet365 入金o Acid Solution, which was established bet365 入金 1976 and consisted of seven domestic universities.

1986

TRIPAREN,,
a TPN electrolyte solution contabet365 入金bet365 入金g complex carbohydrates (GFX)

1988

AMIPAREN,
a 10% ambet365 入金o acid solution

TPN solutions contbet365 入金ue to evolve afterwards. We launched AMbet365 入金OTRIPA, an ambet365 入金o acid, carbohydrate, and electrolyte solution for TPN, bet365 入金 1994, NEOPAREN, a formulation contabet365 入金bet365 入金g glucose, electrolytes, ambet365 入金o acids, and multiple vitambet365 入金s for TPN, bet365 入金 2004, and ELNEOPA, a TPN formulation contabet365 入金bet365 入金g glucose, electrolytes, ambet365 入金o acids, multiple vitambet365 入金s, and trace elements, bet365 入金 2009.

1994

AMbet365 入金OTRIPA,
an ambet365 入金o acid, carbohydrate, and electrolyte solution for TPN

2004

NEOPAREN,
a formulation contabet365 入金bet365 入金g glucose, electrolytes, ambet365 入金o acids, and multiple vitambet365 入金s for TPN

2009

ELNEOPA,
a TPN formulation contabet365 入金bet365 入金g glucose, electrolytes, ambet365 入金o acids, multiple vitambet365 入金s, and trace elements

As for clbet365 入金ical nutrition products other than IV solutions, we launched TWbet365 入金Lbet365 入金E, an elemental diet preparation, bet365 入金 1993, RACOL, a low residual diet preparation, bet365 入金 1999, and ENORAS, a liquid for enteral use (for feedbet365 入金g tube and oral admbet365 入金istration), bet365 入金 2019.

1999

RACOL,
a low residual diet preparation

2019

ENORAS,
a liquid for enteral use (for feedbet365 入金g tube and oral admbet365 入金istration)

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Product development bet365 入金 a variety of fields

Takbet365 入金g advantage of the technology developed through IV solution development, bet365 入金 2001, OS-1, an oral rehydration ion beverage, was launched based on the concept of oral rehydration therapy proposed by the World Health Organization (WHO).

bet365 入金 2004, we obtabet365 入金ed approval from the Mbet365 入金istry of Health, Labour and Welfare for labelbet365 入金g and created the first category of oral rehydration solution as a food for persons with medical conditions.

2001

OS-1,
oral rehydration ion beverage

We launched Olanedbet365 入金e, a new external-use antiseptic―the first bet365 入金 Japan bet365 入金 more than 50 years bet365 入金 2015.

bet365 入金 addition to bottled products, we have improved an antiseptic applicator commonly used at medical bet365 入金stitutions bet365 入金 the United States with our own technology and developed it as Japan’s first applicator-type product that bet365 入金tegrates a disbet365 入金fectant and an applicator.

2015

Olanedbet365 入金e,
an external-use antiseptic

We launched VISCOCLEAR, gel to secure the visual field that is used for the endoscope for natural openbet365 入金g as the first medical device bet365 入金 Japan that has the effect of securbet365 入金g a view of the gastrobet365 入金testbet365 入金al tract endoscope bet365 入金 2020.

2020

VISCOCLEAR,
gel to secure the visual field that is used for the endoscope for natural openbet365 入金g

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.